Segall Bryant & Hamill LLC Buys 34,781 Shares of Veracyte, Inc. (NASDAQ:VCYT)

Segall Bryant & Hamill LLC increased its position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 8.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 468,655 shares of the biotechnology company's stock after buying an additional 34,781 shares during the period. Segall Bryant & Hamill LLC owned about 0.60% of Veracyte worth $13,896,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in VCYT. Jones Financial Companies Lllp boosted its stake in Veracyte by 49.7% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 237 shares during the last quarter. Versant Capital Management Inc boosted its stake in Veracyte by 1,267.6% during the 1st quarter. Versant Capital Management Inc now owns 930 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 862 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Veracyte during the 4th quarter valued at $64,000. Sterling Capital Management LLC boosted its stake in Veracyte by 810.2% during the 4th quarter. Sterling Capital Management LLC now owns 2,421 shares of the biotechnology company's stock valued at $96,000 after acquiring an additional 2,155 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in Veracyte during the 4th quarter valued at $152,000.

Veracyte Price Performance

Shares of VCYT traded down $0.71 during mid-day trading on Friday, hitting $23.51. The company's stock had a trading volume of 1,613,012 shares, compared to its average volume of 921,085. The firm has a 50-day moving average price of $27.15 and a 200 day moving average price of $32.75. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of 57.34 and a beta of 2.07. Veracyte, Inc. has a fifty-two week low of $19.73 and a fifty-two week high of $47.32.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Needham & Company LLC reduced their price target on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Stephens restated an "overweight" rating and issued a $45.00 price target on shares of Veracyte in a research report on Wednesday, March 26th. Wall Street Zen downgraded shares of Veracyte from a "buy" rating to a "hold" rating in a research report on Saturday, June 28th. UBS Group decreased their target price on shares of Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Finally, Guggenheim dropped their price target on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Veracyte presently has an average rating of "Moderate Buy" and a consensus target price of $40.90.

Veracyte Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.